



Our Reference: BLA 125668/o

Octapharma Pharmazeutika Produktionsges.m.b.H.

Attention: Mr. Stanley Ammons

February 6, 2018

Sent by email

Dear Mr. Ammons:

We are reviewing your December 28, 2017, biologics license application (BLA), for Immune Globulin Subcutaneous (Human). We determined that the following information is necessary to continue our review:

Please clarify if gammanorm® and Cutaquig are manufactured in an identical manner. Please detail the differences (if any) and how they may have affected clinical use of gammanorm®.

The review of this submission is on-going and issues may be added, expanded upon, or modified.

Please submit your response to this information request as an amendment to this file by February 8, 2018, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is December 29, 2018.

Please send an email message acknowledging receipt of this request.

If you have any questions, please contact me.

Sincerely,
Edward Thompson
Regulatory Project Manager
FDA/CBER/OBRR/RPMS